Literature DB >> 27268041

In-vivo comparison of the neurotoxic potencies of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA.

Anna Kutschenko1, Anja Manig2, Marie-Christine Reinert2, Angelika Mönnich2, David Liebetanz2.   

Abstract

Three botulinum neurotoxin type A (BoNT/A) products, incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA, all manufactured by different methods, are employed in clinical practice. Comparing the three BoNT/A products is difficult because their concentrations and volumes differ and the precise dose equivalence ratio is not known. We aimed to compare the neurotoxic potencies by a systematic analysis of injected volume and dose. The potency of BoNT in inducing hind limb paresis was assessed by analyzing the wheel-running performance of mice. To standardize the volume, the effect of an identical dose of incobotulinumtoxinA dissolved in different volumes of saline (15, 10, 5, and 2μl) was studied in four groups of mice (n=13-15). The potencies of the BoNT products were then compared by injecting identical volumes (10μl) containing different doses into both hind leg muscles. Mice injected with incobotulinumtoxinA showed a volume-dependent reduction in wheel-running, with larger volumes inducing more intense paresis. A standardized volume containing the same number of mouse units of the BoNT/A products produced different degrees of paresis. The conversion ratio of incobotulinumtoxinA and onabotulinumtoxinA is estimated to be between 1:0.75 and 1:0.5. OnabotulinumtoxinA displayed a two-fold greater potency than abobotulinumtoxinA. Doses of onabotulinumtoxinA and abobotulinumtoxinA that produce an identical severity of pareses even result in the same duration of pareses. This wheel-running assay allows one to compare the neurotoxic potency of different volumes and doses of the BoNT products in vivo. Our results argue against common clinical practice because incobotulinumtoxinA and onabotulinumtoxinA are not readily interchangeable and a two-fold dose of abobotulinumtoxinA is needed to induce an effect identical to onabotulinumtoxinA. In addition, this emphasizes that the duration of BoNT-induced effect is the same as long as equipotent doses of BoNT are injected.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  AbobotulinumtoxinA; IncobotulinumtoxinA; Neurotoxic potency; OnabotulinumtoxinA; Volume-dependency; Wheel-running performance

Mesh:

Substances:

Year:  2016        PMID: 27268041     DOI: 10.1016/j.neulet.2016.06.001

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  12 in total

Review 1.  Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology.

Authors:  Marco Pirazzini; Ornella Rossetto; Roberto Eleopra; Cesare Montecucco
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

Review 2.  Pharmacological differences and clinical implications of various botulinum toxin preparations: a critical appraisal.

Authors:  A Ferrari; M Manca; V Tugnoli; L Alberto
Journal:  Funct Neurol       Date:  2018 Jan/Mar

3.  Subcutaneous BoNT/A Injection for Intractable Pain and Disability in Complex Regional Pain Syndrome: A Case Report.

Authors:  Yan Tereshko; Chiara Dalla Torre; Christian Lettieri; Enrico Belgrado; Gian Luigi Gigli; Mariarosaria Valente
Journal:  Toxins (Basel)       Date:  2022-06-16       Impact factor: 5.075

4.  A Novel Running Wheel Mouse Model for Botulism and Its Use for the Evaluation of Postsymptom Antitoxin Efficacy.

Authors:  Arieh Schwartz; Alon Ben David; Mordechai Hotoveli; Eyal Dor; Eran Diamant; Arik Vivyorka; Osnat Rosen; Amram Torgeman; Ran Zichel
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

5.  The use of the dynamic weight bearing test to assess the effects of acute, intramuscularly administered botulinum neurotoxin type A1 in rats.

Authors:  Sylvie Cornet; Cindy Périer; Stéphanie Wagner; Emile Andriambeloson; Bruno Pouzet; Mikhail Kalinichev
Journal:  Toxicon X       Date:  2020-05-23

Review 6.  Critical Analysis of Neuronal Cell and the Mouse Bioassay for Detection of Botulinum Neurotoxins.

Authors:  Sabine Pellett; William H Tepp; Eric A Johnson
Journal:  Toxins (Basel)       Date:  2019-12-07       Impact factor: 4.546

Review 7.  Botulinum Toxin Type A to Improve Facial Symmetry in Facial Palsy: A Practical Guideline and Clinical Experience.

Authors:  Carla de Sanctis Pecora; Danielle Shitara
Journal:  Toxins (Basel)       Date:  2021-02-18       Impact factor: 4.546

8.  Comparison of neurotoxic potency between a novel chinbotulinumtoxinA with onabotulinumtoxinA, incobotulinumtoxinA and lanbotulinumtoxinA in rats.

Authors:  Ya Feng; Wuchao Liu; Lizhen Pan; Cong Jiang; Chengxi Zhang; Yuxuan Lu; Zhiyu Nie; Lingjing Jin
Journal:  Drug Des Devel Ther       Date:  2017-06-28       Impact factor: 4.162

9.  OnabotulinumtoxinA Displays Greater Biological Activity Compared to IncobotulinumtoxinA, Demonstrating Non-Interchangeability in Both In Vitro and In Vivo Assays.

Authors:  David Rupp; Greg Nicholson; David Canty; Joanne Wang; Catherine Rhéaume; Linh Le; Lance E Steward; Mark Washburn; Birgitte P Jacky; Ron S Broide; Wolfgang G Philipp-Dormston; Mitchell F Brin; Amy Brideau-Andersen
Journal:  Toxins (Basel)       Date:  2020-06-13       Impact factor: 4.546

10.  Comparative Pharmacodynamics Study of 3 Different Botulinum Toxin Type A Preparations in Mice.

Authors:  Seongsung Kwak; Won-Ho Kang; Chang-Hoon Rhee; Gi-Hyeok Yang; Deu John M Cruz
Journal:  Dermatol Surg       Date:  2020-12       Impact factor: 2.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.